Source comparison
PT-141 FAQ: Comparison Table
Before writing, this table compares PT-141 (bremelanotide) to other peptides and pharmacological agents used in sexual function research, highlighting mechanism, onset, duration, and administration route differences. PT-141 (Bremelanotide) MC3R/MC4R agonist. C
This comparison does not assign a generated winner or score.
- Before writing, this table compares PT-141 (bremelanotide) to other peptides and pharmacological agents used in sexual function research, highlighting mechanism, onset, duration, and administration route differences.
- PT-141 (Bremelanotide)
- MC3R/MC4R agonist. Central nervous system activation of sexual desire pathways
- Subcutaneous injection
- 30–60 minutes
- 4–8 hours
- Only centrally-acting peptide with FDA approval for sexual dysfunction; works independent of vascular function
- Melanotan II
- Non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R)
- 6–12 hours
- Broader receptor activity causes skin darkening and higher cardiovascular adverse event rate; not suitable for clinical use
- Sildenafil (Viagra)
- PDE5 inhibitor. Increases cGMP, promotes vasodilation
- Oral tablet
- 4–6 hours
- Peripheral vascular mechanism; no effect on central desire pathways; requires sexual stimulation to be effective
- Tadalafil (Cialis)
- PDE5 inhibitor. Longer half-life than sildenafil
- 30–120 minutes
- 24–36 hours
- Same peripheral mechanism as sildenafil but extended duration; daily low-dose option available
- Kisspeptin
- Stimulates GnRH release. Upstream regulator of reproductive hormones
- Intravenous infusion
- Variable
- Research-stage
- Not yet practical for sexual function enhancement. Studied for reproductive endocrinology
- Oxytocin
- Neuropeptide. Promotes pair bonding, social behavior, and orgasmic response
- Intranasal or subcutaneous
- 15–30 minutes
- 1–3 hours
- Context-dependent effects; enhances emotional connection but does not directly increase libido